

INPLASY PROTOCOL

To cite: Hua et al. Human UCB MSC versus placebo for effect on kidney fibrosis. Inplasy protocol 2022100104. doi: 10.37766/inplasy2022.10.0104

Received: 26 October 2022

Published: 26 October 2022

Corresponding author:
Zi Bo Hua

2081225820@qq.com

Author Affiliation:
China medical university

Support: China medical university.

Review Stage at time of this submission: Formal screening of search results against eligibility criteria.

Conflicts of interest:
None declared.

Human UCB MSC versus placebo for effect on kidney fibrosis

Hua, ZB¹; Lv, YC².

Review question / Objective: Human UCB MSC versus placebo for effect on kidney fibrosis

Condition being studied: Renal fibrosis is the final outcome of long-term chronic kidney disease, and the kidney will lose its basic function. This experiment will explore the effect of Human UCB MSC for effect on kidney fibrosis.

Main outcome(s): Correlation analysis of Human UCB MSC treatment on renal fibrosis.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 26 October 2022 and was last updated on 26 October 2022 (registration number INPLASY2022100104).

INTRODUCTION

Review question / Objective: Human UCB MSC versus placebo for effect on kidney fibrosis.

Condition being studied: Renal fibrosis is the final outcome of long-term chronic kidney disease, and the kidney will lose its basic function. This experiment will explore the effect of Human UCB MSC for effect on kidney fibrosis.

METHODS

Participant or population: Now, the analysis is not used on human clinical trial, so this analysis participant are trial animal (mice rats pig).

Intervention: Human UCB MSC group.

Comparator: Placebo group.

Study designs to be included: Meta analysis.

Eligibility criteria: Kidney fibrosis level.

Information sources: CNKI Pubmed
CNKI
Pubmed.

Main outcome(s): Correlation analysis of Human UCB MSC treatment on renal fibrosis.

Quality assessment / Risk of bias analysis:
Review Manager.

Strategy of data synthesis: Using Review Manager to data analysis ($I^2 > 50\%$, $P < 0$ having heterogeneity) The random effect model is used when there is heterogeneity, and the fixed effect model is used when there is no heterogeneity.

Subgroup analysis: differert ways of kidney fibrosis like Diabetes, Chronic nephritis, Trauma.

Sensitivity analysis: we delate one of the RCT that be choiced in finally paper and monitoring changes in relevance and effectiveness.

Country(ies) involved: China.

Keywords: Human UCB MSC; kidney fibrosis.

Contributions of each author:

Author 1 - Zi Bo Hua.

Author 2 - Lv Yuan Chen.